CLA
TEVA icon

Carnegie Lake Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Carnegie Lake Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.32M Sell
97,900
-2,500
-2% -$83.3K 1.24% 22
2026
Q1 		$3.02M Hold
100,400
– – 1.2% 22
2025
Q4 		$3.13M Sell
100,400
-1,200
-1% -$29.6K 1.19% 22
2025
Q3 		$2.05M Sell
101,600
-2,250
-2% -$39.5K 0.79% 33
2025
Q2 		$1.74M Buy
103,850
+18,500
+22% +$299K 0.69% 39
2025
Q1 		$1.31M Buy
85,350
+16,400
+24% +$293K 0.53% 54
2024
Q4 		$1.52M Hold
68,950
– – 0.61% 45
2024
Q3 		$1.24M Buy
+68,950
New +$1.21M 0.49% 51

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Carnegie Lake Advisors's TEVA Position: Q2 2026 in Review

Carnegie Lake Advisors reduced its Teva Pharmaceuticals (TEVA) stake by 2.5% in Q2 2026, selling an estimated $83.3K and leaving 97,900 shares worth $3.32M. The position accounts for 1.24% of the portfolio, ranked #22.

Carnegie Lake Advisors first reported a position in TEVA in Q3 2024 and has held it in 8 quarters since. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Carnegie Lake Advisors held 97,900 shares of Teva Pharmaceuticals worth $3.32M as of Q2 2026.
  • Carnegie Lake Advisors sold 2,500 Teva Pharmaceuticals shares in Q2 2026, an estimated $83.3K.
  • Teva Pharmaceuticals made up 1.24% of Carnegie Lake Advisors's portfolio in Q2 2026, its #22 holding.
  • Carnegie Lake Advisors first reported a position in Teva Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Carnegie Lake Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.